01 / phase
Phase is not a verdict.
Earlier-phase work often concentrates on feasibility and safety. Later study phases may ask more focused questions, but phase alone does not tell a reader whether a result is reliable, applicable, or final.
Public records, read with context
Trial Tracker
A regionalized way to read registered clinical trials and major planned studies of ibogaine and noribogaine: what a record says, what it does not say, and which details deserve the closest attention.
This is a neutral cataloging framework, not enrollment assistance or a recommendation to participate in any study.
Regional index
Start with the record, then the jurisdiction.
Trial registration is shaped by different systems and rules. Geographic context can affect how a study is registered, described, monitored, updated, and eventually reported.
United States
Look for an NCT identifier and the dated fields within the public registry record. Status labels and listed locations are administrative details, not evidence of outcomes.
European context
EU-CTR entries should be read alongside their protocol and country-level context. Regional regulatory structures can influence the public detail available at different stages.
Other regions
Where a public registry record is available, note the registry, sponsor, jurisdiction, study dates, and whether the entry points to results or a publication.
A record is a starting point
The fields that give a trial its shape.
Records are easier to compare when their design choices are kept separate. Phase, endpoints, sample size, sponsor type, and current status each answer a different question.
02 / endpoints
Read the primary endpoint first.
A primary endpoint defines the central outcome a protocol intends to evaluate. Secondary outcomes can add context, but they should not replace the main prespecified question when comparing records.
03 / design
Count is not the same as strength.
Sample size matters, yet it sits beside allocation, blinding, control arms, follow-up, and monitoring. The best reading considers the design as a whole rather than one number in isolation.
Reading registration entries
Identifiers help you locate a study. They do not settle its meaning.
An NCT number is an identifier used by ClinicalTrials.gov; an EU-CTR record belongs to the European clinical-trial system. In either case, begin with the official entry, its version dates, and its stated protocol details rather than a summary elsewhere.
A
Compare stated purpose with stated endpoint. A broad study title can sit beside a narrow primary measure. The endpoint clarifies what the protocol is actually structured to assess.
B
Identify the sponsor type. Academic, industry, and government sponsors can operate under different incentives and reporting practices; the label is context, not a shortcut to credibility.
C
Check the update trail. Dates, changed recruitment status, amended outcomes, and absent results can all matter when judging how current a public record is.
Quality markers
A concise checklist for preliminary evidence.
Randomization, blinding, and a control arm can reduce some forms of bias, while planned safety monitoring indicates that risk oversight is part of the protocol. These features need to be interpreted in relation to the actual study question, participant group, and follow-up period.
The general logic is well established: randomized controlled trials are designed to compare interventions under specified conditions, but their findings still require careful reading of methods, limitations, and the population studied.
“A trial listing is an index to a question. It is not a substitute for the protocol, the results, or a careful appraisal of both.”
Status and limitations
Follow outcomes responsibly.
What does a registry status tell a reader?
A registry status is a last-known administrative label, not a result. It may indicate recruiting, active not recruiting, completed, terminated, withdrawn, or an unknown status, but it does not itself establish whether an intervention was effective or safe.
Why can registry information be incomplete?
Entries can lag behind protocol changes, recruitment changes, publication, or results posting. A completed study may not yet have public results, and an entry can lack the context needed to interpret later claims. The broader clinical trial process is more than a registry status field.
How should a reader follow up without over-reading?
Use registry identifiers to find later results, peer-reviewed publications, and official updates. Keep uncertainty visible when results are absent or preliminary, and return to the site’s research primer for a grounded reading framework.
Catalog purpose
Keep the public record in proportion.
This tracker is designed for people interested in preliminary ibogaine research who want to separate registered questions, last-known status, and eventual outcomes. For a broader view of the topic, return to the Prelimogaine Research overview.
Neutral context matters.
For independent context around treatment-location information without treating a listing as a clinical recommendation, see ibogaine treatment locations.
Safety and ethics context